Sequenta

Sequenta is a venture funded biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status. A profound revolution in the cost of DNA sequencing has enabled the company to develop brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes. The incredible diversity created by these genes are at the heart of a large number of conditions critical to human health and disease allowing the company to be in a position to inform a large number of clinical decisions using a single powerful assay.

The company was founded in 2008 by entrepreneurs who previously founded ParaAllele BioScience, a successful startup company sold to Affymetrix in 2005.

Sequenta headquartered in United States, North America, operates in the Biotechnology, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $2.6B in funding across 60 round(s). With a team of 51-100 employees, Sequenta is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Sequenta, raised $13.0M. Discover more about their projects, partnerships, and impact on our platform.